“We don’t have any purpose-built technologies for the treatment of VT (ventricular tachycardia), and when I had a chance to look at what Field was building and the opportunity here to build out a new space and a new sector, it was very exciting to me,” Field Medical CEO Mark Turco explains regarding new areas for pulsed field ablation (PFA) innovation. In this episode of the Vanguards of Healthcare podcast, Turco and Field Medical Founder Steven Mickelsen sit down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the potential benefits of the company’s next-generation PFA technology and how it’s designed to address the more demanding areas of cardiac arrhythmias, starting with VT. They dive further into the commercial strategy for its VERITAS VT and FIELD-PULSE pivotal studies, after promising first-in-human trial results.